1
|
Li Y, Qiu J, Gao P, Zhai L, Bai ZJ, Chen HJ. KI-Catalyzed Oxidative Cyclization of Enamines and tBuONO to Access Functional Imidazole-4-Carboxylic Derivatives. J Org Chem 2022; 87:15380-15388. [DOI: 10.1021/acs.joc.2c01943] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- Yingchun Li
- Shaanxi Key Laboratory of Phytochemistry, College of Chemistry and Chemical Engineering, Baoji University of Arts and Sciences, Baoji 721013, Shaanxi, P. R. China
| | - Jixia Qiu
- Shaanxi Key Laboratory of Phytochemistry, College of Chemistry and Chemical Engineering, Baoji University of Arts and Sciences, Baoji 721013, Shaanxi, P. R. China
| | - Peng Gao
- Shaanxi Key Laboratory of Phytochemistry, College of Chemistry and Chemical Engineering, Baoji University of Arts and Sciences, Baoji 721013, Shaanxi, P. R. China
| | - Le Zhai
- Shaanxi Key Laboratory of Phytochemistry, College of Chemistry and Chemical Engineering, Baoji University of Arts and Sciences, Baoji 721013, Shaanxi, P. R. China
| | - Zi-Jing Bai
- Shaanxi Key Laboratory of Phytochemistry, College of Chemistry and Chemical Engineering, Baoji University of Arts and Sciences, Baoji 721013, Shaanxi, P. R. China
| | - Huai-Juan Chen
- Shaanxi Key Laboratory of Phytochemistry, College of Chemistry and Chemical Engineering, Baoji University of Arts and Sciences, Baoji 721013, Shaanxi, P. R. China
| |
Collapse
|
2
|
Komogortsev AN, Lichitsky BV, Karibov TT, Melekhina VG. Multicomponent synthesis of allomaltol containing 2-aminooxazoles and acid-catalyzed recyclization into substituted furo[3,2-b]pyrans. Tetrahedron 2022. [DOI: 10.1016/j.tet.2022.132836] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
3
|
Spasov A, Ozerov A, Vassiliev P, Kosolapov V, Gurova N, Kucheryavenko A, Naumenko L, Babkov D, Sirotenko V, Taran A, Litvinov R, Borisov A, Klochkov V, Merezhkina D, Miroshnikov M, Uskov G, Ovsyankina N. Synthesis and multifaceted pharmacological activity of novel quinazoline NHE-1 inhibitors. Sci Rep 2021; 11:24380. [PMID: 34934125 PMCID: PMC8692498 DOI: 10.1038/s41598-021-03722-w] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2021] [Accepted: 12/09/2021] [Indexed: 11/20/2022] Open
Abstract
The Na+/H+ exchanger isoform 1 (NHE-1) attracts ongoing attention as a validated drug target for the management of cardiovascular and ocular diseases owing to cytoprotective, anti-ischemic and anti-inflammatory properties of NHE-1 inhibitors. Herein we report novel NHE-1 inhibitors realized via functionalization of N1-alkyl quinazoline-2,4(1H,3H)-dione and quinazoline-4(3H)-one with N-acylguanidine or 3-acyl(5-amino-1,2,4-triazole) side chain. Lead compounds show activity in a nanomolar range. Their pharmacophoric features were elucidated with neural network modeling. Several compounds combine NHE-1 inhibition with antiplatelet activity. Compound 6b reduces intraocular pressure in rats and effectively inhibits the formation of glycated proteins. Compounds 3e and 3i inhibit pro-inflammatory activation of murine macrophages, LPS-induced interleukin-6 secretion and also exhibit antidepressant activity similar to amiloride. Hence, novel compounds represent an interesting starting point for the development of agents against cardiovascular diseases, thrombotic events, excessive inflammation, long-term diabetic complications and glaucoma.
Collapse
Affiliation(s)
- Alexander Spasov
- grid.445050.00000 0000 8790 3085Department of Pharmacology & Bioinformatics, Volgograd State Medical University, Volgograd, Russia 400131 ,grid.445050.00000 0000 8790 3085Scientific Center for Innovative Drugs, Volgograd State Medical University, Volgograd, Russia 400087
| | - Alexander Ozerov
- grid.445050.00000 0000 8790 3085Scientific Center for Innovative Drugs, Volgograd State Medical University, Volgograd, Russia 400087 ,grid.445050.00000 0000 8790 3085Department of Pharmaceutical & Toxicological Chemistry, Volgograd State Medical University, Volgograd, Russia 400131
| | - Pavel Vassiliev
- grid.445050.00000 0000 8790 3085Department of Pharmacology & Bioinformatics, Volgograd State Medical University, Volgograd, Russia 400131 ,grid.445050.00000 0000 8790 3085Scientific Center for Innovative Drugs, Volgograd State Medical University, Volgograd, Russia 400087
| | - Vadim Kosolapov
- grid.445050.00000 0000 8790 3085Department of Pharmacology & Bioinformatics, Volgograd State Medical University, Volgograd, Russia 400131 ,grid.445050.00000 0000 8790 3085Scientific Center for Innovative Drugs, Volgograd State Medical University, Volgograd, Russia 400087
| | - Natalia Gurova
- grid.445050.00000 0000 8790 3085Department of Pharmacology & Bioinformatics, Volgograd State Medical University, Volgograd, Russia 400131 ,grid.445050.00000 0000 8790 3085Scientific Center for Innovative Drugs, Volgograd State Medical University, Volgograd, Russia 400087
| | - Aida Kucheryavenko
- grid.445050.00000 0000 8790 3085Department of Pharmacology & Bioinformatics, Volgograd State Medical University, Volgograd, Russia 400131
| | - Ludmila Naumenko
- grid.445050.00000 0000 8790 3085Department of Pharmacology & Bioinformatics, Volgograd State Medical University, Volgograd, Russia 400131
| | - Denis Babkov
- Department of Pharmacology & Bioinformatics, Volgograd State Medical University, Volgograd, Russia, 400131. .,Scientific Center for Innovative Drugs, Volgograd State Medical University, Volgograd, Russia, 400087.
| | - Viktor Sirotenko
- grid.445050.00000 0000 8790 3085Department of Pharmacology & Bioinformatics, Volgograd State Medical University, Volgograd, Russia 400131 ,grid.445050.00000 0000 8790 3085Scientific Center for Innovative Drugs, Volgograd State Medical University, Volgograd, Russia 400087
| | - Alena Taran
- grid.445050.00000 0000 8790 3085Department of Pharmacology & Bioinformatics, Volgograd State Medical University, Volgograd, Russia 400131 ,grid.445050.00000 0000 8790 3085Scientific Center for Innovative Drugs, Volgograd State Medical University, Volgograd, Russia 400087
| | - Roman Litvinov
- grid.445050.00000 0000 8790 3085Department of Pharmacology & Bioinformatics, Volgograd State Medical University, Volgograd, Russia 400131 ,grid.445050.00000 0000 8790 3085Scientific Center for Innovative Drugs, Volgograd State Medical University, Volgograd, Russia 400087
| | - Alexander Borisov
- grid.445050.00000 0000 8790 3085Scientific Center for Innovative Drugs, Volgograd State Medical University, Volgograd, Russia 400087
| | - Vladlen Klochkov
- grid.445050.00000 0000 8790 3085Department of Pharmacology & Bioinformatics, Volgograd State Medical University, Volgograd, Russia 400131
| | - Darya Merezhkina
- grid.445050.00000 0000 8790 3085Department of Pharmacology & Bioinformatics, Volgograd State Medical University, Volgograd, Russia 400131
| | - Mikhail Miroshnikov
- grid.445050.00000 0000 8790 3085Department of Pharmacology & Bioinformatics, Volgograd State Medical University, Volgograd, Russia 400131 ,grid.445050.00000 0000 8790 3085Scientific Center for Innovative Drugs, Volgograd State Medical University, Volgograd, Russia 400087
| | - Georgy Uskov
- grid.445050.00000 0000 8790 3085Department of Pharmacology & Bioinformatics, Volgograd State Medical University, Volgograd, Russia 400131
| | - Nadezhda Ovsyankina
- grid.445050.00000 0000 8790 3085Department of Pharmacology & Bioinformatics, Volgograd State Medical University, Volgograd, Russia 400131
| |
Collapse
|
4
|
Morishita K, Ito Y, Otake K, Takahashi K, Yamamoto M, Kitao T, Ozawa SI, Hirono S, Shirahase H. Synthesis and Evaluation of a Novel Series of 2,7-Substituted-6-tetrazolyl-1,2,3,4-tetrahydroisoquinoline Derivatives as Selective Peroxisome Proliferator-Activated Receptor γ Partial Agonists. Chem Pharm Bull (Tokyo) 2021; 69:333-351. [PMID: 33790079 DOI: 10.1248/cpb.c20-00841] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
A novel series of 7-substituted-2-[3-(2-furyl)acryloyl]-6-tetrazolyl-1,2,3,4-tetrahydroisoquinoline derivatives were synthesized to clarify structure-activity relationships for peroxisome proliferator-activated receptor γ (PPARγ) partial agonist activity and identify more efficacious PPARγ partial agonists with minor adverse effects. Among the derivatives synthesized, compound 26v with a 2-(2,5-dihydropyrrol-1-yl)-5-methyloxazol-4-ylmethoxy group at the 7-position of the tetrahydroisoquinoline structure exhibited stronger PPARγ agonist and antagonist activities (EC50 = 6 nM and IC50 = 101 nM) than previously reported values for compound 1 (EC50 = 13 nM and IC50 = 512 nM). Compound 26v had very weak protein tyrosine phosphatase 1B (PTP1B) inhibitory activity and showed higher oral absorption (Cmax = 11.4 µg/mL and area under the curve (AUC) = 134.7 µg·h/mL) than compound 1 (Cmax = 7.0 µg/mL and AUC = 63.9 µg·h/mL) in male Sprague-Dawley (SD) rats. A computational docking calculation revealed that 26v bound to PPARγ in a similar manner to that of compound 1. In male Zucker fatty rats, 26v and pioglitazone at 10 and 30 mg/kg for 4 weeks similarly reduced plasma triglyceride levels, increased plasma adiponectin levels, and attenuated increases in plasma glucose levels in the oral glucose tolerance test, while only pioglitazone decreased hematocrit values. In conclusion, 6-tetrazolyl-1,2,3,4-tetrahydroisoquinoline derivatives provide a novel scaffold for selective PPARγ partial agonists and 26v attenuates insulin resistance possibly by adiponectin enhancements with minor adverse effects.
Collapse
Affiliation(s)
- Ko Morishita
- Drug Discovery Research Department, Kyoto Pharmaceutical Industries, Ltd
| | - Yuma Ito
- Drug Discovery Research Department, Kyoto Pharmaceutical Industries, Ltd
| | - Kazuya Otake
- Drug Discovery Research Department, Kyoto Pharmaceutical Industries, Ltd
| | - Kenji Takahashi
- Drug Discovery Research Department, Kyoto Pharmaceutical Industries, Ltd
| | - Megumi Yamamoto
- Drug Discovery Research Department, Kyoto Pharmaceutical Industries, Ltd
| | - Tatsuya Kitao
- Drug Discovery Research Department, Kyoto Pharmaceutical Industries, Ltd
| | | | | | - Hiroaki Shirahase
- Drug Discovery Research Department, Kyoto Pharmaceutical Industries, Ltd
| |
Collapse
|
5
|
Lee J, Yoon SS, Thuy PX, Moon EY. Synovial Cell Migration is Associated with B Cell Activating Factor Expression Increased by TNFα or Decreased by KR33426. Biomol Ther (Seoul) 2020; 28:405-413. [PMID: 32753567 PMCID: PMC7457168 DOI: 10.4062/biomolther.2020.110] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2020] [Revised: 07/10/2020] [Accepted: 07/13/2020] [Indexed: 02/06/2023] Open
Abstract
Fibroblast-like synoviocytes (FLS) play a crucial role in initiating rheumatoid arthritis. B-cell activating factor (BAFF) plays a role in FLS survival as well as in B cell maturation and maintenance. Here, we investigated whether tumor necrosis factor (TNF)-α-induced BAFF expression controls FLS migration and whether BAFF expression in FLS could be regulated by KR33426 which is the inhibitor of BAFF binding to BAFF receptors (BAFF-R) by using MH7A synovial cells transfected with the SV40 T antigen. More TNF-α-treated cells migrated compared to the control. TNF-α increased BAFF expression in FLS, significantly. FLS migration was inhibited by the transfection with BAFF-siRNA. KR33426 also inhibited BAFF expression increased by TNF-α treatment in FLS as judged by western blotting, PCR, and transcriptional activity assay. Kinases including JNK, p38 and Erk were activated by TNF-α treatment. While JNK and p38 were inhibited by KR33426 treatment, no changes in Erk were observed. Transcription factors including p65, c-Fos, CREB and SP1 were enhanced by TNF-α treatment. Among them, c-Fos was inhibited by KR33426 treatment. Small interference(si)-RNA of c-fos decreased BAFF transcriptional activity. FLS migration induced by TNF-α was inhibited by the transfection with BAFF-siRNA. KR33426 increased Twist, Snail, Cadherin-11 and N-Cadherin. In contrast, KR33426 decreased E-cadherin and TNF-α-enhanced CCL2. Taken together, our results demonstrate that synovial cell migration via CCL2 expression could be regulated by BAFF expression which is decreased by KR33426 and c-Fos-siRNA. It suggests for the first time that the role of BAFF-siRNA on FLS migration might be matched in the effect of KR33426 on BAFF expression.
Collapse
Affiliation(s)
- Jiyoung Lee
- Department of Bioscience and Biotechnology, Sejong University, Seoul 05006, Republic of Korea
| | - Sung Sik Yoon
- Department of Bioscience and Biotechnology, Sejong University, Seoul 05006, Republic of Korea
| | - Pham Xuan Thuy
- Department of Bioscience and Biotechnology, Sejong University, Seoul 05006, Republic of Korea
| | - Eun-Yi Moon
- Department of Bioscience and Biotechnology, Sejong University, Seoul 05006, Republic of Korea
| |
Collapse
|
6
|
Roslan II, Ng KH, Gondal MA, Basheer C, Dastageer MA, Jaenicke S, Chuah GK. Visible Light-Mediated Coupling of Thioureas and 1,3-Dicarbonyls: Towards a Leaving Group-Free Synthesis of Aminothiazoles. Adv Synth Catal 2018. [DOI: 10.1002/adsc.201701565] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
- Irwan Iskandar Roslan
- Department of Chemistry; National University of Singapore; 3 Science Drive 3 Singapore 117543
| | - Kian-Hong Ng
- Department of Chemistry; National University of Singapore; 3 Science Drive 3 Singapore 117543
| | - Mohammed Ashraf Gondal
- Physics Department; King Fahd University of Petroleum & Minerals; Dhahran 31261 Saudi Arabia
| | - Chanbasha Basheer
- Chemistry Department; King Fahd University of Petroleum & Minerals; Dhahran 31261 Saudi Arabia
| | - Mohamed A. Dastageer
- Physics Department; King Fahd University of Petroleum & Minerals; Dhahran 31261 Saudi Arabia
| | - Stephan Jaenicke
- Department of Chemistry; National University of Singapore; 3 Science Drive 3 Singapore 117543
| | - Gaik-Khuan Chuah
- Department of Chemistry; National University of Singapore; 3 Science Drive 3 Singapore 117543
| |
Collapse
|
7
|
Tahir S, Badshah A, Hussain RA. Guanidines from ‘toxic substances’ to compounds with multiple biological applications – Detailed outlook on synthetic procedures employed for the synthesis of guanidines. Bioorg Chem 2015; 59:39-79. [DOI: 10.1016/j.bioorg.2015.01.006] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2014] [Revised: 01/13/2015] [Accepted: 01/19/2015] [Indexed: 11/25/2022]
|
8
|
Song Y, Buchwald P. TNF superfamily protein-protein interactions: feasibility of small- molecule modulation. Curr Drug Targets 2015; 16:393-408. [PMID: 25706111 PMCID: PMC4408546 DOI: 10.2174/1389450116666150223115628] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2014] [Revised: 02/10/2015] [Accepted: 02/11/2015] [Indexed: 01/09/2023]
Abstract
The tumor necrosis factor (TNF) superfamily (TNFSF) contains about thirty structurally related receptors (TNFSFRs) and about twenty protein ligands that bind to one or more of these receptors. Almost all of these cell surface protein-protein interactions (PPIs) represent high-value therapeutic targets for inflammatory or immune modulation in autoimmune diseases, transplant recipients, or cancers, and there are several biologics including antibodies and fusion proteins targeting them that are in various phases of clinical development. Small-molecule inhibitors or activators could represent possible alternatives if the difficulties related to the targeting of protein-protein interactions by small molecules can be addressed. Compounds proving the feasibility of such approaches have been identified through different drug discovery approaches for a number of these TNFSFR-TNFSF type PPIs including CD40-CD40L, BAFFR-BAFF, TRAIL-DR5, and OX40-OX40L. Corresponding structural, signaling, and medicinal chemistry aspects are briefly reviewed here. While none of these small-molecule modulators identified so far seems promising enough to be pursued for clinical development, they provide proof-of-principle evidence that these interactions are susceptible to small-molecule modulation and can serve as starting points toward the identification of more potent and selective candidates.
Collapse
Affiliation(s)
| | - Peter Buchwald
- Diabetes Research Institute, Miller School of Medicine, University of Miami, 1450 NW 10 Ave (R-134), Miami, FL 33136, USA.
| |
Collapse
|
9
|
Šačkus A, Bričkutė D, Paliulis O, Sløk FA. Synthesis of Heterocyclic Analogs of α-aminoadipic Acid and its Esters Based on Imidazo[2,1-b][1,3]Thiazole. J Heterocycl Chem 2014. [DOI: 10.1002/jhet.2090] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Algirdas Šačkus
- Department of Organic Chemistry; Kaunas University of Technology; Kaunas LT-50254 Lithuania
- Institute of Synthetic Chemistry; Kaunas University of Technology; Kaunas LT-50254 Lithuania
| | - Diana Bričkutė
- Department of Organic Chemistry; Kaunas University of Technology; Kaunas LT-50254 Lithuania
| | - Osvaldas Paliulis
- Institute of Synthetic Chemistry; Kaunas University of Technology; Kaunas LT-50254 Lithuania
| | | |
Collapse
|
10
|
Rauf MK, Imtiaz-ud-Din, Badshah A. Novel approaches to screening guanidine derivatives. Expert Opin Drug Discov 2013; 9:39-53. [PMID: 24261559 DOI: 10.1517/17460441.2013.857308] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION Compounds containing guanidine moiety, originating both from natural and synthetic sources, have found potential applications in both synthetic and medicinal chemistry. Indeed, guanidine functionality can be found in many natural and pharmaceutical products as well as in cosmetic ingredients produced by synthetic methods. AREAS COVERED This review covers the latest developments in the research undertaken for the therapeutic application of newly synthesized guanidine derivatives including: small peptides and peptidomimetics. This article encompasses the selected literature published in the last three decades with a focus on the novel approaches for screening of lead drug candidates with their pharmacological action. EXPERT OPINION Guanidines, as they are both organically based and also hydrophilic in nature, have undergone a mammoth amount of screening and testing to discover promising lead structures with a CN3 core, appropriate for potential future drug development. The compounds have the potential to be neurodegenerative therapeutic options, as well as: anti-inflammatory, anti-protozoal, anti-HIV, chemotherapeutic, anti-diabetic agents and so on. It is true that guanidine-based compounds of natural sources also, like synthetic and virtually designed drugs, have been of significant interest and have the potential to be useful therapeutic options in the future. As for now, however, there is not sufficient data to support their use in a number of the suggested areas, and further studies are required.
Collapse
|
11
|
Zhang L, Peng XM, Damu GLV, Geng RX, Zhou CH. Comprehensive review in current developments of imidazole-based medicinal chemistry. Med Res Rev 2013; 34:340-437. [PMID: 23740514 DOI: 10.1002/med.21290] [Citation(s) in RCA: 482] [Impact Index Per Article: 43.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Imidazole ring is an important five-membered aromatic heterocycle widely present in natural products and synthetic molecules. The unique structural feature of imidazole ring with desirable electron-rich characteristic is beneficial for imidazole derivatives to readily bind with a variety of enzymes and receptors in biological systems through diverse weak interactions, thereby exhibiting broad bioactivities. The related research and developments of imidazole-based medicinal chemistry have become a rapidly developing and increasingly active topic. Particularly, numerous imidazole-based compounds as clinical drugs have been extensively used in the clinic to treat various types of diseases with high therapeutic potency, which have shown the enormous development value. This work systematically gives a comprehensive review in current developments of imidazole-based compounds in the whole range of medicinal chemistry as anticancer, antifungal, antibacterial, antitubercular, anti-inflammatory, antineuropathic, antihypertensive, antihistaminic, antiparasitic, antiobesity, antiviral, and other medicinal agents, together with their potential applications in diagnostics and pathology. It is hoped that this review will be helpful for new thoughts in the quest for rational designs of more active and less toxic imidazole-based medicinal drugs, as well as more effective diagnostic agents and pathologic probes.
Collapse
Affiliation(s)
- Ling Zhang
- Laboratory of Bioorganic & Medicinal Chemistry, School of Chemistry and Chemical Engineering, Southwest University, Chongqing 400715, People's Republic of China
| | | | | | | | | |
Collapse
|
12
|
Sączewski F, Balewski Ł. Biological activities of guanidine compounds, 2008 - 2012 update. Expert Opin Ther Pat 2013; 23:965-95. [PMID: 23617396 DOI: 10.1517/13543776.2013.788645] [Citation(s) in RCA: 64] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION Compounds incorporating guanidine moiety have found many practical applications in diverse areas of chemistry, such as nucleophilic organocatalysis, anion recognition and coordination chemistry. Moreover, guanidine functional group is found in natural products, pharmaceuticals and cosmetic ingredients produced by synthetic methods. Thus, knowledge of their biological activities and therapeutic uses is of utmost importance for researchers involved in drug discovery processes. AREAS COVERED In this review the authors highlight the continued development and therapeutic applications of newly synthesized guanidine-containing compounds including small peptides and peptidomimetics incorporating arginine. The review presents patents and patent applications filed in the years 2008 - 2012 with emphasis placed on new mechanisms of pharmacological action of guanidine derivatives. EXPERT OPINION While guanidines are often thought of as strong organic bases and compounds hydrophilic in nature, over the last 4 years there has been an enormous increase in discovery of new promising lead structures with guanidine core, suitable for development of potential drugs acting at central nervous system, anti-inflammatory agents, anti-diabetic and chemotherapeutic agents as well as cosmetics.
Collapse
Affiliation(s)
- Franciszek Sączewski
- Medical University of Gdańsk, Department of Chemical Technology of Drugs, Al. Gen. Hallera 107, 80-416 Gdańsk, Poland.
| | | |
Collapse
|
13
|
|
14
|
Lee GH, Oh JM, Kim HS, Yoon WK, Yi KY, Yang Y, Han SH, Lee S, Moon EY. KR33426, [2-(2,5-dichlorophenyl)-5-methyloxazol-4yl]carbonylguanidine, is a novel compound to be effective on mouse systemic lupus erythematosus. Eur J Pharmacol 2011; 668:459-66. [PMID: 21827747 DOI: 10.1016/j.ejphar.2011.07.026] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2011] [Revised: 07/01/2011] [Accepted: 07/21/2011] [Indexed: 01/19/2023]
Abstract
B cell-activating factor (BAFF) is a key regulator of B lymphocyte development. Signals from BAFF are transmitted through binding to a specific BAFF receptor (BAFF-R). Here, we established screening method to find a specific inhibitor for the interference of BAFF-BAFF-R interactions. We screened oxazole-4-carbonylguanidine derivatives and selected KR33426, [2-(2,5-dichlorophenyl)-5-methyloxazol-4yl]carbonylguanidine, as a candidate to interfere BAFF-BAFF-R interactions. KR33426 inhibited BAFF-mediated anti-apoptotic effect on splenocytes as judged by hypodiploid cell formation. KR33426 also increased the degradation of procaspase-3 that was inhibited by BAFF protein. In addition, we examined whether KR33426 was effective on the treatment of systemic lupus erythematosus-like symptom in MRL(lpr/lpr) mouse. When 5 or 10mg/kg KR33426 was intraperitoneally administered to MRL(lpr/lpr) mice for 4 weeks, histopathological changes were ameliorated in the narrowed space between renal glomerulus and glomerulus capsule. KR33426 reduced B220(+) B cell population and B cell mitogen, lipopolysaccharide-stimulated lymphocyte proliferation in splenocytes. KR33426 attenuated an increase in CD43(-)IgM(+) immature pro-B and a decrease in CD21(+) IgM(+) T2-B and IgD(+) IgM(-)recirculating-B cells on B cell development. Data show that KR33426 inhibits BAFF-BAFF-R interactions and it is effective on the treatment of systemic lupus erythematosus-like symptom in MRL(lpr/lpr) mice. Thus, it suggests that KR33426 is a novel candidate to develop anti-autoimmune therapeutics by the interference of BAFF-BAFF-R interactions, specifically.
Collapse
Affiliation(s)
- Geun-Hee Lee
- Department of Bioscience and Biotechnology, Sejong University, Seoul 143-747, Republic of Korea
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Moon EY, Yi KY, Lee S. An increase in B cell apoptosis by interfering BAFF-BAFF-R interaction with small synthetic molecules. Int Immunopharmacol 2011; 11:1523-33. [PMID: 21620999 DOI: 10.1016/j.intimp.2011.05.009] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2011] [Revised: 05/10/2011] [Accepted: 05/11/2011] [Indexed: 10/18/2022]
Abstract
B cell-activating factor (BAFF) transmitted signals through binding to specific BAFF receptors (BAFF-R) to regulate B cell survival and development. We used MTT assay to examine the cytotoxicity of chemicals, flow cytometry analysis to measure BAFF-BAFF-R interactions, and western blotting to detect BAFF protein. Here, we established screening method to find specific compounds to interfere with BAFF-BAFF-R interactions in WIL2-NS B lymphoblast cells. According to screening (imidazol-4-ylcarbonyl)guanidine or (oxazol-4-ylcarbonyl)guanidine derivatives, we selected KR32592, KR32673, KR33232, KR33341 and KR33426 as candidates to interfere with BAFF-BAFF-R interaction. No cytotoxicity was detected by KR32592, KR33232, and KR33426 at the concentration of 5 μM, and by KR32673, and KR33341 at the concentration of 0.5 μM. Cell population with BAFF-BAFF-R interactions was reduced by the pre-incubation of chemicals with human BAFF-murine CD8 (BAFF-muCD8). Cell population with BAFF-BAFF-R interactions was also decreased by pre-exposure of WIL2-NS cells to chemicals prior to the incubation with BAFF-muCD8. Chemicals also inhibited LPS-stimulated BAFF production from splenocytes. All these effects of chemicals may contribute to the inhibition of BAFF-mediated anti-apoptosis. These data demonstrate that chemicals interfering with BAFF-BAFF-R interaction may be screened with our experimental condition. It suggests that BAFF-BAFF-R interaction could be a chemical target to develop therapeutics for BAFF-mediated autoimmune diseases.
Collapse
Affiliation(s)
- Eun-Yi Moon
- Department of Bioscience and Biotechnology, Sejong University, Seoul 143-747, Republic of Korea.
| | | | | |
Collapse
|
16
|
Berlinck RGS, Burtoloso ACB, Trindade-Silva AE, Romminger S, Morais RP, Bandeira K, Mizuno CM. The chemistry and biology of organic guanidine derivatives. Nat Prod Rep 2010; 27:1871-907. [DOI: 10.1039/c0np00016g] [Citation(s) in RCA: 94] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|